Wegovy (Semaglutide) for Weight Loss: A UK Guide

Few medicines have reshaped the conversation about weight as quickly as Wegovy. In the space of a couple of years it has gone from clinical-trial headlines to a name people recognise, and with that fame has come a fair amount of confusion — about what it actually is, how well it works, how to access it in the UK, and what it does and does not do for your body.

This guide sets out to answer those questions clearly and honestly. It is educational: Wegovy is a prescription-only medicine, and nothing here is a recommendation to take it or an offer to supply it. If you are considering it, the right first step is always a conversation with your GP or pharmacist, who can assess whether it is safe and suitable for you. What we can do is explain the science, the evidence and the realistic picture — including the parts the headlines tend to skip.

What is Wegovy?

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injection made by Novo Nordisk. It is licensed specifically for chronic weight management, which sets it apart from Ozempic — the same drug at a lower dose, licensed for type 2 diabetes. They are not interchangeable, and only a prescriber can decide which product and dose is appropriate.

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists. If you want the mechanism explained from the ground up, our guide to how GLP-1 weight-loss injections work is a good companion to this article. In short, Wegovy is a “pure” GLP-1 medicine — it acts on a single hormone pathway, which is one of the ways it differs from newer dual-action drugs.

How it works

Your gut naturally releases a hormone called GLP-1 after you eat, which helps signal fullness. The catch is that natural GLP-1 is broken down within minutes. Semaglutide is engineered to resist that breakdown and to bind to albumin in the blood, giving it a half-life of roughly one week — which is what makes once-weekly dosing possible.

Once active, it works in several ways at once:

• It reduces appetite by acting on GLP-1 receptors in the appetite centres of the brain.
• It slows gastric emptying, so food stays in the stomach longer and you feel fuller for longer.
• It stimulates insulin in a glucose-dependent way and suppresses glucagon, helping steady blood sugar.

The combined effect for most people is simply eating less without the constant hunger that usually undermines a calorie deficit. That is the core of how it produces weight loss.

What the evidence shows

Wegovy’s reputation rests on the STEP clinical trial programme, one of the most substantial bodies of evidence for any weight-management medicine.

In STEP 1, adults without diabetes lost an average of 14.9% of their body weight over 68 weeks alongside diet and exercise support, compared with 2.4% on placebo. Around 86% lost at least 5% of their weight, and just over half lost 15% or more.

Crucially, the effect held up over time. STEP 5 followed people to two years and found mean weight loss of 15.2%, with more than three-quarters maintaining at least a 5% reduction. In a direct comparison, STEP 8 showed semaglutide 2.4 mg roughly doubling the weight loss of liraglutide (Saxenda) — 15.8% versus 6.4%.

Perhaps the most significant finding came from outside weight loss altogether. The SELECT trial, involving more than 17,000 people with established heart disease and overweight or obesity but not diabetes, found that semaglutide reduced major adverse cardiac events by 20%. This made Wegovy the first weight-loss treatment approved for cardiovascular risk reduction — a benefit that goes beyond the number on the scales.

Wegovy is best understood as a treatment for a chronic condition, not a quick fix. The evidence is genuinely strong, but it is strongest when the medicine sits alongside lasting changes to how you eat and move.

Dosing: a slow, deliberate build-up

Wegovy is not started at its full strength. The dose is increased gradually over about four months to let the body adjust and to limit side effects. A typical schedule looks like this:

In January 2026 the MHRA also approved a higher-dose 7.2 mg version for adults with a BMI of 30 or above — the first approval at that strength anywhere — which trials link to around 20% weight loss. As with every dose, the escalation and the target are decisions for the prescribing clinician.

Getting Wegovy in the UK

There are two routes, and they are quite different.

On the NHS, Wegovy is available only through specialist Tier 3 and 4 weight-management services, under NICE guidance (TA964). Broadly, that means a BMI of 35 or above with at least one weight-related health condition, or a BMI of 30–34.9 with a comorbidity for those referred to specialist services, with lower thresholds for some ethnic groups. Treatment is capped at two years and must come with dietary and lifestyle support. Notably, Wegovy has not been extended into everyday GP prescribing in the way Mounjaro has — it remains a specialist-service medicine. For eligible patients the prescription charge is £9.90 per item in England, and it is free in Scotland, Wales and Northern Ireland.

Privately, it is more widely available, and costs vary with dose:

A first year reaching the maintenance dose can total around £2,140. Wherever it is obtained, it should be through a legitimate, regulated prescriber who assesses your suitability first — not bought unregulated online. If you have medical questions about eligibility or cost, your GP or pharmacist is the right person to ask.

Side effects and safety

Wegovy carries the side-effect profile common to its class. The most frequent are gastrointestinal:

• Nausea — reported by around 44% of people at some point in STEP 1, usually mild to moderate and concentrated during the dose build-up
• Diarrhoea, vomiting and constipation
• Mild injection-site reactions
• Headache and fatigue, mostly early on
• A small, transient rise in heart rate

There are also rarer but more serious considerations. Wegovy is not suitable for people with a history of pancreatitis, and it carries an increased risk of gallbladder problems. Like other drugs in its class, it carries a warning about thyroid C-cell tumours and is contraindicated in anyone with a personal or family history of medullary thyroid cancer or MEN2. Combined with insulin or certain diabetes medicines, it can raise the risk of low blood sugar. These are exactly the reasons the medicine has to be prescribed and monitored — a prescriber will screen for all of them before starting treatment.

What happens to your body — and your face

One aspect the marketing rarely mentions is how the body changes when weight comes off quickly. Substantial or rapid loss can reduce facial fat, producing the gaunt look often nicknamed “Ozempic face”, and can leave loose skin and reduced muscle mass across the body. This is a consequence of losing weight fast rather than a specific drug effect — but it is real, and worth planning for.

Losing weight at a steady pace, eating enough protein and staying active — particularly with resistance exercise — all help protect skin, muscle and facial volume along the way. For some people, once their weight has stabilised, non-surgical options can help refine areas that respond less well to diet alone. Muscle-focused treatments such as EMSculpt work on tone rather than weight, while fat freezing targets specific stubborn, pinchable pockets. It is worth being clear that these are body-contouring treatments, not weight-loss treatments, and they are complementary to — never a substitute for — a medically supervised weight-management plan.

Stopping treatment

Because obesity is a chronic condition, Wegovy is designed for long-term use, and the question of what happens when you come off it matters a great deal. Appetite tends to return once treatment stops, and studies consistently show that much of the lost weight is regained without continued support. We explore this in detail in our guide to what happens when you stop weight-loss injections. Any decision to stop should be made with the clinician who prescribed it, ideally with a plan for maintaining your progress.

The honest bottom line

Wegovy is a genuinely effective, well-studied medicine with benefits that reach beyond weight into cardiovascular health. It is also a prescription-only treatment with real side effects, meaningful costs, and a tendency for weight to return if it is stopped without a plan. It is not a shortcut, and it is not for everyone — the only way to know whether it is right for you is a proper medical assessment with your GP or pharmacist.

If your goal after losing weight is to refine your shape, address stubborn areas or rebuild tone, that is where we can help. The team at Fat Reduction Bristol offers honest, no-pressure consultations about our non-surgical body-contouring options — a conversation about what is realistic for your body, once your weight is stable. Book a consultation and we will give you a straight answer about whether we can help.